Gadolinium, a contrast agent used in MRI and MRA scans has been linked to a painful condition affecting the skin and joints as well as impaired brain function.
The Food and Drug Administration has announced that it will require new safety measures for certain contrast agents, or "dyes," used to enhance magnetic resonance imaging (MRI) scans, because small amounts of the compounds can be retained in the brain and other tissues.
READ MORE at Forbes.com
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.
READ MORE at FDA.gov
On Thursday, a law firm announced it was representing Chuck Norris in a suit against three different companies for $10 million in damages. Norris and his wife, Gena, claim that she has gadolinium deposition disease from medical scans taken five years ago. But what is gadolinium? And how controversial is its use?
READ MORE at Newsweek.com
Gadolinium chelates are widely used as contrast media for magnetic resonance imaging. The approved gadolinium-based contrast agents (GBCAs) have historically been considered safe and well tolerated when used at recommended dosing levels. However, for nearly a decade, an association between GBCA administration and the development of nephrogenic systemic fibrosis (NSF) has been recognized in patients with severe renal impairment.
READ MORE at the National Institute of Health
Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication - Retained in Body; New Class Warnings
The FDA issued a Drug Safety Communication today about gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) to alert health care professionals and patients about gadolinium retention in the body and to provide information on how to mitigate the risk. The FDA is requiring a new class warning for all GBCAs about gadolinium remaining in the body for months or years after receiving the drug.
READ MORE at FDA.gov
Today we have released our fourth research paper on gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) administered for contrast-enhanced MRIs. The paper is titled “Gadolinium Retention from Contrast MRIs in 70 Cases with Normal Renal Function – 24-hour Urine Test Results”.
READ MORE at GadoliniumToxicity.com